Jenny Bearn - Publications, H-index & Citations

A STUDY OF SULFATOXYMELATONIN EXCRETION AND GONADOTROPIN STATUS DURING WEIGHT-GAIN IN ANOREXIA-NERVOSA

IF7.6

2018-01-03

OAAI

Keaney, F; Crimlisk, H; Bearn, J

IF7.6

2018-01-02

PREAI

BEARN, J; TREASURE, J; MURPHY, M; FRANEY, C; ARENDT, J; WHEELER, M; CHECKLEY, SA

CLOZAPINE

A STUDY OF THE EFFECTS OF DESIPRAMINE TREATMENT ALONE AND IN COMBINATION WITH L-TRIIODOTHYRONINE ON 6-SULFATOXYMELATONIN EXCRETION IN DEPRESSED-PATIENTS

IF7.6

2018-01-02

OAAI

KERWIN, RW; PILOWSKY, LS; REVELY, A; EVERALL, IP; BEARN, J; LAUNER, M

Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism

IF7.6

2018-01-02

PREAI

BEARN, J; FRANEY, C; ARENDT, J; CHECKLEY, SA

ADDICTION

IF5.3

2013-02-11

OAAI

Djamshidian, Atbin; Sanotsky, Yanosh; Matviyenko, Yuriy; O'Sullivan, Sean S.; Sharman, Stephen; Selikhova, Marianna; Fedoryshyn, Ludmyla; Filts, Yuriy; Bearn, Jenny; Lees, Andrew J.; Averbeck, Bruno B.

Route of drug use and its implications for drug effect, risk of dependence and health consequences

DRUG AND ALCOHOL REVIEW

IF2.6

2009-05-29

PREAI

Strang, J; Bearn, J; Farrell, M; Finch, E; Gossop, M; Griffiths, P; Marsden, J; Wolff, K

In-patient detoxification procedures, treatment retention, and post-treatment opiate use: Comparison of lofexidine plus naloxone, lofexidine plus placebo, and methadone

Salivary cortisol during opiate dependence and withdrawal

IF3.6

2007-04-01

PREAI

McCambridge, J.; Gossop, M.; Beswick, T.; Best, D.; Bearn, J.; Rees, S.; Strang, J.

Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine detoxification treatments (vol 8, pg 49, 2003)

IF2.6

2006-06-09

PREAI

Bearn, J; Buntwal, N; Papadopoulos, A; Checkley, S

Induction of patients with moderately severe methadone dependence onto buprenorphine

IF2.6

2006-06-09

PREAI

Beswick, T; Best, D; Rees, S; Bearn, J; Gossop, M; Strang, J

Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine detoxification treatments

IF2.6

2006-06-09

PREAI

Glasper, A; Reed, LJ; de Wet, CJ; Gossop, M; Bearn, J

The impact of naloxone/lofexidine combination treatment on the opiate withdrawal syndrome 纳洛酮/洛非西定联合治疗对阿片戒断综合征的影响

IF2.6

2006-06-09

PREAI

Beswick, T; Best, D; Rees, S; Bearn, J; Gossop, M; Strang, J

Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review

IF2.6

2006-06-09

PREAI

Bearn, J; Bennett, J; Martin, T; Gossop, M; Strang, J

Is opiate detoxification unsafe in pregnancy?

IF3.6

2004-07-15

117

PREAI

McDonough, M; Kennedy, N; Glasper, A; Bearn, J

JOURNAL OF SUBSTANCE ABUSE TREATMENT

IF4

2003-06-01

PREAI

Luty, J; Nikolaou, V; Bearn, J

Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2003-05-03

254

OAAI

Strang, J; McCambridge, J; Best, D; Beswick, T; Bearn, J; Rees, S; Gossop, M

Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study

PSYCHOPHARMACOLOGY

IF3.3

2001-03-05

105

PREAI

Curran, HV; Kleckham, J; Bearn, J; Strang, J; Wanigaratne, S

Neural responses associated with cue evoked emotional states and heroin in opiate addicts

Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification

IF3.6

2000-08-01

189

OAAI

Sell, LA; Morris, JS; Bearn, J; Frackowiak, RSJ; Friston, KJ; Dolan, RJ